Therini Bio Reports Promising Phase 1a Results For THN391 A Novel Therapy Targeting Alzheimer’s And Eye Diseases

Therini Bio, a clinical-stage biotech innovator, has announced encouraging results from its Phase 1a trial for THN391, a first-in-class monoclonal antibody aimed at tackling neurodegenerative diseases by reducing fibrin-induced neuroinflammation. The company’s unique approach targets a lesser-known but critical mechanism: fibrin deposits that drive inflammation and neuronal damage where blood vessels malfunction—key drivers in diseases like Alzheimer’s and Diabetic Macular Edema (DME).

In the Phase 1a trial conducted on healthy volunteers, THN391 was found to be safe and well-tolerated. There were no serious adverse events, no impact on blood clotting or fibrinolysis, and no immune reactions to the drug. Importantly, the drug showed a half-life compatible with monthly dosing, making future treatment more convenient.

Dr. Tara Nickerson, CEO of Therini Bio, mentioned, “Our trial results are a significant milestone for this novel drug class. By focusing on vascular dysfunction and chronic inflammation, we are going after the root causes of neurodegeneration - not just the symptoms. We’re deeply motivated by this data and are pushing forward with confidence.”

The findings will be formally presented at the Alzheimer’s Association International Conference 2025 (AAIC 25) on July 30 in Toronto. Therini Bio is preparing to launch two Phase 1b trials shortly—one focused on Alzheimer’s Disease and the other on Diabetic Macular Edema. Backed by compelling preclinical data, THN391 could potentially bring new hope to millions affected by neurodegenerative diseases worldwide.